Literature DB >> 11601909

Hepatitis C virus core protein modulates the interferon-induced transacting factors of Jak/Stat signaling pathway but does not affect the activation of downstream IRF-1 or 561 gene.

A Basu1, K Meyer, R B Ray, R Ray.   

Abstract

Hepatitis C virus (HCV) has a propensity to cause chronic infection, with a low proportion of patients exhibiting a sustained response to interferon-alpha (IFNalpha) therapy. An earlier report suggested that HCV inhibits IFNalpha-induced signal transduction through the Jak/Stat pathway by preventing the formation of the transacting factor ISGF3 complex, although the effect on downstream pathway and the specific viral protein responsible for inhibition of IFNalpha-mediated signal transduction were not elucidated. HCV core protein displays a number of intriguing functional properties and has been implicated in virus-mediated pathogenesis. In this study, we have analyzed the effect of core protein upon IFNalpha- or IFNgamma-induced regulation of the Jak/Stat signaling pathway. HCV core protein expression exhibited a reduced Stat1 expression in IFN-treated mammalian cells. A gel retardation assay suggested a reduced level of formation of the transacting factors, GAF and ISGF3, in IFN-treated cells. Further studies from protein expression and RNase protection assay revealed that the reduced level of GAF or ISGF3 formation could be attributed to modulation of Stat1 protein expression, an important player for innate immunity in host defense mechanism. However, these modulatory effects did not interfere with the activation of the downstream effector genes, IRF-1 and 561, in IFN-treated cells. Stable transfectants of cells after introduction of a plasmid DNA encoding both the structural and the nonstructural proteins of HCV also exhibited a similar effect. Taken together, these results suggest that although expression of the core protein alone or with other HCV proteins modulate transacting factors of Jak/Stat signaling pathway, expression of the downstream effector genes IRF-1 and 561 remains unaffected upon IFN treatment and may contribute to host defense mechanism. Copyright 2001 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11601909     DOI: 10.1006/viro.2001.1100

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  26 in total

1.  Characterization of type I interferon pathway during hepatic differentiation of human pluripotent stem cells and hepatitis C virus infection.

Authors:  Joseph Ignatius Irudayam; Deisy Contreras; Lindsay Spurka; Aparna Subramanian; Jenieke Allen; Songyang Ren; Vidhya Kanagavel; Quoclinh Nguyen; Arunachalam Ramaiah; Kalidas Ramamoorthy; Samuel W French; Andrew S Klein; Vincent Funari; Vaithilingaraja Arumugaswami
Journal:  Stem Cell Res       Date:  2015-08-15       Impact factor: 2.020

2.  Hepatitis C virus core protein blocks interferon signaling by interaction with the STAT1 SH2 domain.

Authors:  Wenyu Lin; Sun Suk Kim; Elaine Yeung; Yoshitaka Kamegaya; Jason T Blackard; Kyung Ah Kim; Michael J Holtzman; Raymond T Chung
Journal:  J Virol       Date:  2006-09       Impact factor: 5.103

3.  Effects of silymarin on hepatitis C virus and haem oxygenase-1 gene expression in human hepatoma cells.

Authors:  Vania Bonifaz; Ying Shan; Richard W Lambrecht; Susan E Donohue; Darcy Moschenross; Herbert L Bonkovsky
Journal:  Liver Int       Date:  2008-08-07       Impact factor: 5.828

4.  Blockade of virus infection by human CD4+ T cells via a cytokine relay network.

Authors:  Ann M Davis; Kristan A Hagan; Loderick A Matthews; Gagan Bajwa; Michelle A Gill; Michael Gale; J David Farrar
Journal:  J Immunol       Date:  2008-05-15       Impact factor: 5.422

Review 5.  Silencing suppressors: viral weapons for countering host cell defenses.

Authors:  Liping Song; Shijuan Gao; Wei Jiang; Shuai Chen; Yanjun Liu; Ling Zhou; Wenlin Huang
Journal:  Protein Cell       Date:  2011-04-27       Impact factor: 14.870

6.  Immunocompetent mouse models to evaluate intrahepatic T cell responses to HCV vaccines.

Authors:  Wenbo Yu; Branka Grubor-Bauk; Ranajoy Mullick; Saumitra Das; Eric J Gowans
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

7.  Natural interferon-beta plus ribavirin therapy led to sustained virological response after seven unsuccessful courses of anti-viral treatment in a chronic hepatitis C patient.

Authors:  Tatsuo Kanda; Shingo Nakamoto; Makoto Arai; Tatsuo Miyamura; Shuang Wu; Keiichi Fujiwara; Osamu Yokosuka
Journal:  Clin J Gastroenterol       Date:  2013-02-17

8.  Hepatitis C virus-host interactions: Etiopathogenesis and therapeutic strategies.

Authors:  Mohamed Hassan; Denis Selimovic; Abdelouahid El-Khattouti; Hanan Ghozlan; Youssef Haikel; Ola Abdelkader
Journal:  World J Exp Med       Date:  2012-04-20

9.  Regulation of hepatitis C virus replication by interferon regulatory factor 1.

Authors:  Nobuhiko Kanazawa; Masayuki Kurosaki; Naoya Sakamoto; Nobuyuki Enomoto; Yasuhiro Itsui; Tsuyoshi Yamashiro; Yoko Tanabe; Shinya Maekawa; Mina Nakagawa; Cheng-Hsin Chen; Sei Kakinuma; Shigeru Oshima; Tetsuya Nakamura; Takanobu Kato; Takaji Wakita; Mamoru Watanabe
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

10.  Hepatitis C virus core protein upregulates serine phosphorylation of insulin receptor substrate-1 and impairs the downstream akt/protein kinase B signaling pathway for insulin resistance.

Authors:  Sutapa Banerjee; Kousuke Saito; Malika Ait-Goughoulte; Keith Meyer; Ratna B Ray; Ranjit Ray
Journal:  J Virol       Date:  2007-12-26       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.